NewAmsterdam Pharma (NASDAQ:NAMS) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of NewAmsterdam Pharma (NASDAQ:NAMSFree Report) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $48.00 price target on the stock.

NAMS has been the topic of several other research reports. Piper Sandler restated an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Needham & Company LLC restated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Finally, Scotiabank upped their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma has a consensus rating of “Buy” and a consensus price target of $38.17.

Get Our Latest Stock Report on NewAmsterdam Pharma

NewAmsterdam Pharma Stock Performance

NAMS opened at $23.67 on Tuesday. The company’s 50-day simple moving average is $23.63 and its two-hundred day simple moving average is $19.74. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $25.02, for a total value of $213,420.60. Following the completion of the sale, the insider now owns 11,812,033 shares in the company, valued at $295,537,065.66. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold 446,730 shares of company stock worth $11,438,695 in the last 90 days. 19.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Quarry LP raised its stake in NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after acquiring an additional 6,247 shares during the period. Barclays PLC increased its stake in shares of NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares in the last quarter. Bellevue Group AG bought a new stake in shares of NewAmsterdam Pharma during the 3rd quarter valued at $128,000. XTX Topco Ltd bought a new stake in shares of NewAmsterdam Pharma during the 3rd quarter valued at $187,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of NewAmsterdam Pharma by 176.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock valued at $371,000 after buying an additional 14,280 shares in the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

(Get Free Report)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Featured Articles

Analyst Recommendations for NewAmsterdam Pharma (NASDAQ:NAMS)

Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.